Navigation Links
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Date:11/6/2008

a single dose of either intravenous (120 mg/m squared) or oral picoplatin (200, 300 or 400 mg). Four weeks later, they were crossed over to a second single picoplatin dose administered via the alternative route. In the second part of the trial, patients received only a single oral dose of picoplatin (including doses of 50 and 100 mg).

Results showed that oral picoplatin can achieve oral bioavailability of up to 44 percent in the doses tested in the first arm. Results also showed that picoplatin oral bioavailability is linear, and maximum exposure to orally administered picoplatin was achieved at doses of 200 mg or greater. Additionally, following four weeks of dosing with either oral or intravenous picoplatin, only background levels of circulating platinum could be detected, suggesting no drug accumulation between dosing cycles.

There were no differences in pharmacokinetics observed, and all doses were well tolerated with no serious adverse events related to treatment noted following the oral dose. No myelosuppression occurred after oral dosing.

Poniard expects to present additional data from the trial at scientific meetings during 2009.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum- based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... , Sept. 18, 2014  A $3 million grant ... the University of Michigan to establish a national center ... Glenn Center for Aging Research at U-M will focus ... can slow the effects of aging and postpone diseases ... aging that can help develop medications that may help ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
(Date:9/18/2014)... can expect to pay higher employee contributions for their ... resource officers about the impact of the Patient Protection ... Obamacare) conducted by the Darla Moore School of Business ... , Patrick Wright, a professor in strategic human resource ... HR Officers. The survey is distributed to more than ...
(Date:9/18/2014)... to develop tools that would allow them to clearly ... a neuron fires to the resulting behavior in a ... working to develop a range of new tools to ... such tool that provides a new way of mapping ... collaboration between Viviana Gradinaru (BS ,05), assistant professor of ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... much about it. FlameEz.com is launched to provide the latest information ... of the most feared illnesses in middle and old age. ... ... Millions of Americans are affected by chronic inflammation without knowing much ...
... a ,must book-mark site,BETHESDA, Md., Jan. 14 The ... Foundation,s Web site -- www.cff.org -- the ... its "Best of the Web" review of 2008, the ... about cystic fibrosis. , , "This ...
... in French Hospital Market with More Than 130 ... ("Global Med" or the "Company") (OTC Bulletin Board: ... today announced that its subsidiary, Inlog, has licensed ... Serveur" in France) to nineteen additional hospitals during ...
... to Treat Diseases (HTDS) www.htdsmedical.com management ... agreement with Shenzhen Mellow Hope Pharm Industrial Co., ... biggest exporter of Biological Vaccines in China, and ... influenza, tetanus, diphtheria and other diseases; Blood based ...
... Quality Program ReviewsSEATTLE, Jan. 14 MetaStar, ... clinical guidelines and software from Milliman Care ... non-physician medical care reviews throughout the state. ... Milliman Care Guidelines (R) suite, MetaStar now ...
... insulin and oral human growth hormone formulations provide ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ... Cobalamin(TM) oral drug delivery product development programs. The ... B12 oral uptake mechanism to facilitate oral absorption ...
Cached Medicine News:Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 2Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 3Health News:Cystic Fibrosis Foundation Web Site Rated 'Best of the Web' 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 3Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 2Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: